Pelvic serous carcinoma is usually advanced stage at diagnosis, indicating that abdominal spread occurs early in carcinogenesis. Recent discovery of a precursor sequence in the fallopian tube, culminating in serous tubal intraepithelial carcinoma (STIC), provides an opportunity to study early disease events. This study aims to explore novel metastatic routes in STICs. A BRCA1 mutation carrier (patient A) who presented with a STIC and tubal intraluminal shedding of tumor cells upon prophylactic bilateral salpingo-oophorectomy (PBSO) instigated scrutiny of an additional 23 women who underwent a PBSO and 40 patients with pelvic serous carcinoma involving the tubes. Complete serial sectioning of tubes and ovaries of patient A did not reveal invasive carcinoma, but subsequent staging surgery showed disseminated abdominal disease. STIC, intraluminal tumor cells, and abdominal metastases displayed an identical immunohistochemical profile (p53 + /WT1 + / PAX8 + /PAX2 À ) and TP53 mutation. In 16 serous carcinoma patients (40%) tubal intraluminal tumor cells were found, compared with none in the PBSO group. This is the first description of a STIC, which plausibly metastasized without the presence of invasion through intraluminal shedding of malignant surface epithelial cells in the tube and subsequently spread throughout the peritoneal cavity. These findings warrant a reconsideration of the malignant potential of STICs and indicate that intraluminal shedding could be a risk factor for early intraperitoneal metastasis. Although rare in the absence of invasive cancer, we show that intraluminal shedding of tumor cells in the fallopian tubes from serous carcinoma cases are common and a likely route of abdominal spread.
O ver the last decade the classical entity of high-grade serous epithelial ovarian cancer, the most common subtype, has been the subject of a critical reevaluation. Initial discoveries of noninvasive dysplastic changes 1, 2 and early occult invasive carcinomas [3] [4] [5] [6] arising in the fallopian tubes, but not the ovaries, 7 of women at increased cancer risk undergoing preventive salpingo-oophorectomy have cast doubts on the assumed ovarian origin of these cancers. [8] [9] [10] In fact, follow-up studies, which looked more carefully at the fallopian tubes of cancer patients, discovered (pre)invasive involvement of the tubes in as many as 34% to 60% of all serous cancers. [11] [12] [13] This includes many serous carcinomas without a dominant ovarian or tubal mass, which had previously been designated primary peritoneal carcinomas. 12, 14 Taken together, these findings suggest that the majority of high-grade serous "ovarian and peritoneal" carcinomas actually originate outside of these organs, warranting a reclassification to the more inclusive "pelvic serous carcinoma."
The above-described difficulties in assigning the correct tissue of origin can be primarily attributed to the growth pattern of pelvic serous carcinoma. Upon diagnosis, up to 96% of serous carcinomas show some degree of pelvic spread, 15 which in cases with severe destruction of normal anatomy thwarts the assignment of a site of origin. From a current clinical perspective, site of origin has become of limited importance at this point as treatment regimens remain the same, regardless of tubal, ovarian, or peritoneal origin. Increased understanding of early serous carcinogenesis could, however, be vital for future patient management, as it presents the opportunity of detecting and disrupting serous cancer while still confined to the tissue of origin.
With that in mind, the carcinogenetic sequence in the fallopian tube has recently been further elucidated. Several discoveries have strengthened the position of noninvasive severe dysplastic changes, later renamed to serous tubal intraepithelial carcinoma (STIC), as a direct precursor of invasive pelvic serous carcinoma. Like invasive carcinoma, they have a predominantly secretory phenotype and display frequent p53 expression and increased proliferation (Ki67) by immunohistochemistry. 2 Moreover, molecular analysis revealed identical TP53 mutations between STICs and invasive carcinoma within the same patient. 14, 16 Since then, other entities that may occur even earlier in tumor initiation and progression have been described. These include p53 signatures, which show increased p53 expression but are morphologically benign, 16 and secretory cell outgrowths. Like signatures and STICs these latter lesions have a secretory phenotype, and they share aberrant expression of some markers (PAX2 loss), but secretory cell outgrowths do not overexpress p53. [17] [18] [19] STICs and p53 signatures are predominantly found in the infundibulum and fimbriae and thereby coincide with the region where early invasive carcinomas are often discovered. 11, 14, 20 As such, progression from intraepithelial to locally invasive carcinoma and finally distant pelvic spread seems a common way of tumor progression. However, there is circumstantial evidence suggesting that not all cases of pelvic serous carcinoma arising from the fallopian tube follow this path. A number of cases presenting with disseminated peritoneal disease only show intraepithelial carcinoma upon examination. 12, 14 Assuming a causal relationship between STIC and distant metastases, which is strongly implied by the Mu¨llerian/ tubal expression pattern of many of these disseminated tumors (ie, PAX8 + , WT1 + ), [21] [22] [23] this would mean intraepithelial lesions can give rise to distant metastatic disease.
Here we discuss a patient supporting this hypothesis, who presented with a STIC in the fimbriated end of the fallopian tube in conjunction with shed groups of atypical cells lying loose within the fallopian tube lumen and fimbriae.
In addition, we evaluate the prevalence of intraluminal tumor spread in serous cancer and noncancer cases and assess whether intraluminal spread is a commonly traversed route in pelvic serous carcinogenesis.
MATERIALS AND METHODS

Patient Selection
The patient initiating this analysis was a 65-year-old G1P1 (patient A) who presented on April 17, 2012 for a prophylactic bilateral salpingo-oophorectomy (PBSO) because of an increased hereditary risk associated with a BRCA1 germline mutation. The medical history further included a hysterectomy for a menstrual disorder (1991), which did not show any histologic abnormalities.
Subsequent to the identification of this patient, a group of 40 patients with pelvic serous carcinoma either primarily or secondarily involving the fallopian tube was selected (group 1), for which they underwent surgery at the University Medical Center Utrecht, The Netherlands, between January 2000 and April 2012.
A second evaluation consisted of 23 women who underwent a prophylactic removal of the fallopian tubes at the University Medical Center Utrecht between January 2004 and March 2012 (group 2). Of these, 11 were BRCA 1/2 mutation carriers, 1 had Lynch syndrome, and 12 had a positive family history with an unknown mutation status.
Histologic and Immunohistochemical Analysis
Fallopian tube tissue was acquired from all patients. Tissue dissection, preparation, and immunohistochemical analyses were performed as previously described. 24 Antibodies used were directed against p53 (BP-53-12; mouse monoclonal; 1:400 dilution; citrate; Biogenex, Fremont, CA), PAX8 (MRQ-50; mouse monoclonal; 1:200 dilution; EDTA; Cell Marque, Rocklin, CA), PAX2 (EP3251; rabbit polyclonal; 1:50 dilution; EDTA; Abcam, Cambridge, MA), Ki67 (M7240; mouse monoclonal; 1:200 dilution; citrate; Dako, Glostrup, Denmark), CK20 (M-7019; mouse monoclonal; 1:200 dilution; EDTA; Dako), WT1 (WT49; mouse monoclonal; 1:25 dilution; EDTA; Novocastra, Wetzlar, Germany), and CD68 (NCL-CD68-KP1; mouse monoclonal 1:800 dilution; citrate; Novocastra).
Bilateral ovaries and fallopian tubes from patient A were embedded in paraffin in toto. Tissue was examined for the presence of invasive malignancy by serial sectioning and then staining every tenth 4-mm-thick section with hematoxylin and eosin (H&E). Slides from patient A were separately examined by 3 authors (J.G.B., C.A.S., and P.J.v.D.), and slides from all patients in groups 1 and 2 were reviewed by J.G.B. and P.J.D.
Laser Capture Microdissection and TP53 Mutation Analysis
STIC and metastatic cancer from patient A were isolated separately by microdissection (PALM MicroBeam; Zeiss, Jena, Germany). DNA was isolated using Cobas DNA sample preparation kit (Roche, Basel, Switzerland); and exons 4 to 8 of the TP53 gene were screened for mutations using chain terminator sequencing.
RESULTS
Case Description of Patient A and Immunohistochemical Analysis
Histologic examination of the prophylactically removed ovaries and fallopian tubes revealed a STIC in the fimbriae and atypical cells unattached to the tubal epithelium spread throughout the fallopian tube and fimbriae. Subsequent immunohistochemical analysis showed that the atypical unattached cells exhibited an expression profile matching that of high-grade serous carcinoma, showing expression of p53 (3+, >90% of cells), PAX8 (3+, 80%), and WT1 (2+, 80%) and loss of PAX2 (0,100%) and CK20 (0,100%) ( Fig. 1 , fimbriated end in 1F; CK20 not shown), in which a score of 3+ denotes strong nuclear staining, 2+ moderate staining, 1+ weak staining and 0 no staining. In an attempt to localize the source of the intraluminal tumor cells the complete fallopian tubes and ovaries were serially sectioned and examined by H&E staining at 40 mm intervals. This revealed 2 other STICs in the fimbriae, 1 of which showed local surface shedding of tumor cells and had a similar immunohistochemical profile as the intraluminal tumor cells showing expression of p53 (3+, >90% of cells), PAX8 (3+, 100%), WT1 (2+, 70%), and Ki67 (30%) and Fig. 1 ). In addition, 2 solitary groups of atypical cells lying within a cortical ovarian artery and small lymph vessel were identified. There was no evidence of invasive cancer either in the tubes or the ovaries. On the basis of the histopathologic findings tumor markers were assessed (CA-125, 304 U/mL; CA-15.3, 55 U/mL) and a computed tomography scan performed, which showed several lesions in the omentum and the abdominal cavity that were suspect for metastases. A laparoscopic staging procedure was initiated but had to be aborted upon the discovery of bulky upper abdominal (omental) disease. A complete laparotomic debulking was subsequently undertaken. Tumor was found in 2 intraabdominal adhesions (1 adhesion of the small intestine adhered to the vaginal vault and 1 adhesion at the incision site of the earlier PBSO) and in the omentum. These tumor depositions showed an identical expression pattern as the previously identified atypical cells and STIC, with p53 (3+ in 80%, 2+ in >90%), PAX8 (3+ in 50%, 2+ in 80%), WT1 (1+ in 30%), and Ki67 (50%) expression and loss of PAX2 (0,100%) ( Fig. 2) . All (5) sampled pelvic and para-aortic lymph nodes were free of tumor.
Molecular Analysis
TP53 mutation analysis of the STIC and omental metastases revealed an identical missense mutation in exon 6, p.Y220C A > G. The mutation was not perceived in normal ovarian tissue, thereby ruling out the possibility of a germline p.Y220C A > G mutation.
This particular somatic mutation has been reported in 360 tumors in Release 15 of the IARC TP53 mutation database 25 and accounts for 6% of TP53 mutations found in high-grade serous carcinoma, 26 making it one of the more commonly found mutations. cells in the same patient, and in 4 the STIC was found in the same cross-section as the intraluminal tumor cells ( Fig. 3) (Table 1) .
Intraluminal tumor cells were primarily observed in the infundibulum and fimbriae, with 5 of 16 found exclusively in the infundibulum and fimbriae, 9 of 16 both in the infundibulum and ampulla, and 2 of 16 predominantly in the isthmus and ampulla with minor involvement of the infundibulum.
Cases in which intraluminal tumor clumps were solely observed directly adjacent to fulminant tumor growth/STICs within the same cross-section were excluded, as this made distinction between local tumor shedding and true distant intraluminal spread impossible, as were cases in which the epithelium was completely obliterated by the tumor.
Assessment of Intraluminal Tumor Spread in PBSO Cases
Of the 23 patients in group 2, 12 harbored dysplastic changes in their fallopian tubes. No intraluminal tumor cells were found, irrespective of the presence of dysplasia. Eleven of 12 dysplastic changes displayed mild to moderate cytonuclear atypia without extensive loss of cell polarization or a marked increase in proliferative index (Ki67), comparable to the previously described and probably still benign entity of serous tubal intraepithelial lesions/tubal intraepithelial lesions in transition, 27 and 1 showed severe atypia (STIC). None of these lesions showed shedding of surface epithelial cells.
Mimics of Intraluminal Tumor Cells
In most cases intraluminal tumor cells can be readily distinguished from other cells frequently found in the fallopian tube lumen, such as clumps of lymphocytes, on the basis of morphologic assessment in H&E. One possible exception could be groups of intraluminal histiocytes, whose overall cell size and occasionally variable nuclei may in select cases resemble malignant cells in H&E. In these instances a negative p53 stain and low proliferative index can point in the right direction; however, a CD68 stain might be more helpful in making the final distinction.
DISCUSSION
We describe a patient with tubal intraluminal tumor cells and a small STIC as the sole evidence of disease upon prophylactic removal of the fallopian tubes. Reexamination of the fallopian tubes and ovaries in their entirety revealed multiple STICs located in the fimbriae and 2 solitary foci of intravascular/intralymphatic tumor cells in the ovarian cortex, but no invasive cancer. Staging laparoscopy based on these findings revealed widespread abdominal disease. Several arguments can be made for STIC as the source of the distant abdominal depositions rather than a secondary manifestation of a primary peritoneal source or a separate disease process. First, no gynecologic invasive cancer was found and no tumor was seen directly arising from the peritoneal surface, as all peritoneal manifestations were confined to abdominal adhesions and the omentum. Second, STIC, intraluminal tumor cells, and omental tumor depositions displayed identical markers by immunohistochemistry and were shown to harbor identical TP53 mutations.
The omental disease observed in this patient is most likely incited by intraluminal shedding of the tumor cells observed in the fallopian tube into the peritoneum. Once intraperitoneal, the most common way for tumor cells to spread is by following the flow of peritoneal fluid, which is then drained by omental lymphatic vessels. Primary lymphatic spread through the abdomen is implausible in this case, as there was no extensive invasion of the The "Cancer" column documents in which organs invasive cancer was present. Bold denotes where the bulk of tumor tissue was found (which is not necessarily where it originated). lymphatic system, and lymphatic drainage of the gynecologic organs is not directly connected to the omentum but ends at either the para-aortic, iliac, or inguinal lymph nodes, 28, 29 which were all tumor free. Primary hematogenous spread is likewise implausible, as metastases from hematogenous spread are rarely seen when extensive invasion is absent and are more common with recurrence. 29 The singular clumps of tumor cells present in the angiolymphatic system of the ovarian cortex are therefore unlikely to be responsible for the observed widespread peritoneal disease.
Taken together, this, to our knowledge, marks the first time that tubal intraluminal shedding of tumor cells has been highlighted as a mechanism of abdominal spread in the absence of invasion. These findings fit well with previous epidemiological and histologic observations that serous carcinoma becomes high stage early in its development, as they strongly imply that the presence of a "precursor" lesion is sufficient to induce widespread serous carcinoma. Moreover, our observations tie in with previous hypotheses. On the basis of the normal histology of the fimbriae, Kurman and Shih 30 proposed that the extensive angiolymphatic perfusion closely underneath the epithelial surface could provide the basis for early spread without the need for gross invasion. The discovery of intravascular and intralymphatic tumor cells in the ovarian cortex in the current case suggests that this might occur even without microscopic disruption of the basement membrane. Secondly, on the basis of observations in endometrial intraepithelial carcinoma, which is known to shed malignant cells that subsequently spread through the fallopian tube lumen and throughout the pelvis, Wheeler et al 31 proposed that a similar mechanism could be true for STICs. This now seems to be confirmed by our observations of intraluminal tumor depositions and apparent luminal shedding of tumor cells by STICs (Figs. 1, 2) .
Although pior to this study a metastasizing STIC has not been similarly described, there have been several reports of positive peritoneal washings in patients with STICs. 11, 14, [32] [33] [34] In addition, studies retrospectively examining the fallopian tubes of patients with widespread pelvic carcinoma found STICs in a large percentage of patients, with STIC and distant disease displaying the same immunophenotype and TP53 mutations. 12, 14 On the basis of these findings, it is plausible that, as in our case, these STICs were the direct instigators of distant peritoneal spread.
In light of the above, our subsequent aim was to assess the presence of intraluminal tumor spread in pelvic serous carcinoma involving the fallopian tube. On the basis of the rate at which we observed intraluminal tumor cells (ie, 40%), the tubal lumen seems to be a common pathway of spread throughout the pelvic cavity. In addition, tumor cells were primarily found in the infundibulum (87.5%) and in 31.3% solely involved the infundibulum and fimbriae. This coincides with the region in which both STICs and (early) invasive carcinomas are most commonly found in prophylactically removed fallopian tubes. 11, 14, 20 It is important to realize that the exceedingly early tumor spread as here described is likely restricted to pelvic serous carcinoma. It is as much a consequence of the molecular make-up of serous carcinoma, with the acquisition of a driver mutation of TP53 early in carcinogenesis, 26, 35 as of the unique anatomic and histologic properties of the tissue from which it arises: the fimbriae. As such, tumors that rely on a slow accumulation of gene mutations with each mutation attributing to a slight increase in malignant potential would not have the intrinsic capacity of replicating this behavior.
A second consideration should be that the fraction of STICs that metastasize this early is in all likelihood small, even in a population at hereditary high risk. In the present study intraluminal tumor cells were absent in a group of randomly selected PBSO specimens that lacked STICs with a similar level of atypia as in patient A. This may indicate that the capacity to shed tumor cells is acquired only at an advanced stage of dysplasia.
Regarding the clinical consequences of STICs diagnosed on PBSO there is no evidence-based consensus. Most institutions do not act on the diagnosis of a STIC, except in rare cases of STICs found in conjunction with positive peritoneal washings, in which instance small case studies have opted for adjuvant chemotherapy in all but 1 patient and have not seen any recurrences. 14, 34 However, large-scale studies, either retrospectively or prospectively assessing recurrence rates after discovery of an STIC, have not been undertaken, and whether patients with positive peritoneal washings indeed have a higher risk of recurrence and should therefore be treated more elaborately has not yet been addressed. We have started a prospective study to compare different clinical policies, to evaluate risk factors of STIC progression and to assess the value of adding peritoneal washings to the surgical protocol, but this will require a long-term, multicentre approach because of the low incidence of these entities. In addition, we are attempting to retrospectively collect more cases through collaborations. In the meantime, we would suggest adding peritoneal washings to the clinical management of patients undergoing PBSO, as it would be a relatively small implementation with potentially large implications.
Finally, on the basis of our findings we would advocate routine assessment of tumor markers at a single time-point just before PBSO. The current case showed an elevation of tumor markers before staging surgery, which may have been present pre-PBSO as well. The assessment of a preoperative CA-125 should not be confused with using tumor markers and/or ultrasound as periodical screening measures in high-risk patients, which is not considered useful. [36] [37] [38] [39] [40] In summary, we describe tubal intraluminal shedding of tumor cells as a potential way for pelvic serous carcinoma to spread throughout the peritoneal cavity and present a case that implies that this shedding may be a property displayed in the preinvasive STIC stage of serous carcinogenesis. As intraluminal shedding of STICs seems to be a risk factor for early intraperitoneal metastasis, it should be actively assessed during pathologic examination of STIC-harboring fallopian tubes. This increased attention may lead to the identification of a specific STIC phenotype prone to metastasizing, which apart from shedding may include loss of cell orientation and intraepithelial fractures, features recently described, 41 which can both be appreciated in the currently presented STIC.
